key papersKey paper
FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma
Five years on, the higher radiotherapy dose still controlled indolent lymphoma far better: 90 percent of treated sites were free of regrowth after 24 Gy against 70 percent after 4 Gy.
Overview
Long-term follow-up of the FoRT trial (614 target sites in 548 patients) at a median of 73.8 months: 117 local progression events, 27 after 24 Gy and 90 after 4 Gy.
Local progression-free rates were 94.1 percent at two years and 89.9 percent at five years after 24 Gy against 79.8 and 70.4 percent after 4 Gy (hazard ratio 3.46).
Randomised controlled trialChanged practice548 participants89 citations
Authors
Hoskin P, Popova B, Schofield O, et al.
Published
The Lancet Oncology, 2021
Findings
- Five-year local progression-free rate 89.9 percent (95% CI 85.5 to 93.1) after 24 Gy versus 70.4 percent (64.7 to 75.4) after 4 Gy.
- Hazard ratio 3.46 (95% CI 2.25 to 5.33) at a median follow-up of 73.8 months.
What it means
Confirms 24 Gy in 12 fractions as the optimal dose for indolent lymphoma when durable local control is the goal.
Caveats
- Overall survival was not the endpoint and most patients had further systemic options at progression.
Similar pages
not linked directly; found by shared links- Key paperFoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial
Shares FoRT, Marginal zone lymphoma, The Lancet Oncology, Follicular lymphoma.
- PersonCaron A. Jacobson
- TrialZUMA-5
- PersonJohn P. Leonard
- TrialAUGMENT
- TrialGALLIUM
- TreatmentChlorambucil
- TechnologyHypofractionated radiotherapy
Shares FoRT, Marginal zone lymphoma.